Monica Fung1, Eric Jacobsen2, Arnold Freedman2, Daniel Prestes3, Dimitrios Farmakiotis4, Xiangmei Gu3, Paul L Nguyen5, Sophia Koo2,3. 1. Division of Infectious Diseases, University of California, San Francisco. 2. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 3. Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts. 4. Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, Rhode Island. 5. Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.
Abstract
Background: Bendamustine is a potent chemotherapy agent increasingly used to treat indolent non-Hodgkin lymphoma (iNHL). While effective, it causes significant T-cell lymphopenia, which may increase risk of infection. We examined infectious complications associated with bendamustine-containing regimens among older patients with iNHL. Methods: For this Surveillance, Epidemiology, and End Results (SEER)-Medicare cohort study, we identified 9395 patients with iNHL (follicular, marginal zone, Waldenström macroglobulinemia) treated with chemotherapy from 2006 to 2013. Thirteen percent received bendamustine-containing regimens. We compared baseline characteristics and infection incidence rates between patients treated with and without bendamustine. We conducted multivariate Cox proportional hazards regression (adjusting for demographics, comorbidities, disease and treatment characteristics, risk factors for infection, and antimicrobial prophylaxis) to determine infectious risks associated with bendamustine. Results: Bendamustine was associated with an increased risk of both common infections such as bacterial pneumonia (hazard ratio [HR], 1.50 [95% confidence interval {CI}, 1.21-4.85]) and opportunistic infections such as cytomegalovirus (HR, 3.98 [95% CI, 1.40-11.26]), varicella zoster virus (HR, 1.49 [95% CI, 1.18-1.89]), histoplasmosis (HR, 3.55 [95% CI, 1.10-11.42]), and Pneumocystis jirovecii pneumonia (when administered as third-line therapy: HR, 3.32 [95% CI, 1.00-11.11]). Risk of infections was more prominent in patients receiving bendamustine as part of later (third-line and above) regimens, and independently associated with well-established factors such as neutropenia and corticosteroid exposure. Conclusions: Bendamustine is associated with an increased risk of common and opportunistic infections in patients with iNHL. Further prospective investigation into the potential role of antimicrobial prophylaxis is needed in these patients.
Background: Bendamustine is a potent chemotherapy agent increasingly used to treat indolent non-Hodgkin lymphoma (iNHL). While effective, it causes significant T-cell lymphopenia, which may increase risk of infection. We examined infectious complications associated with bendamustine-containing regimens among older patients with iNHL. Methods: For this Surveillance, Epidemiology, and End Results (SEER)-Medicare cohort study, we identified 9395 patients with iNHL (follicular, marginal zone, Waldenström macroglobulinemia) treated with chemotherapy from 2006 to 2013. Thirteen percent received bendamustine-containing regimens. We compared baseline characteristics and infection incidence rates between patients treated with and without bendamustine. We conducted multivariate Cox proportional hazards regression (adjusting for demographics, comorbidities, disease and treatment characteristics, risk factors for infection, and antimicrobial prophylaxis) to determine infectious risks associated with bendamustine. Results:Bendamustine was associated with an increased risk of both common infections such as bacterial pneumonia (hazard ratio [HR], 1.50 [95% confidence interval {CI}, 1.21-4.85]) and opportunistic infections such as cytomegalovirus (HR, 3.98 [95% CI, 1.40-11.26]), varicella zoster virus (HR, 1.49 [95% CI, 1.18-1.89]), histoplasmosis (HR, 3.55 [95% CI, 1.10-11.42]), and Pneumocystis jirovecii pneumonia (when administered as third-line therapy: HR, 3.32 [95% CI, 1.00-11.11]). Risk of infections was more prominent in patients receiving bendamustine as part of later (third-line and above) regimens, and independently associated with well-established factors such as neutropenia and corticosteroid exposure. Conclusions: Bendamustine is associated with an increased risk of common and opportunistic infections in patients with iNHL. Further prospective investigation into the potential role of antimicrobial prophylaxis is needed in these patients.
Authors: Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet Journal: Blood Date: 2005-09-08 Impact factor: 22.113
Authors: Elisabeth M Hodson; Cheryl A Jones; Angela C Webster; Giovanni F M Strippoli; Peter G Barclay; Kathy Kable; Dushyanthi Vimalachandra; Jonathan C Craig Journal: Lancet Date: 2005 Jun 18-24 Impact factor: 79.321
Authors: Douglas C Chang; Lauren A Burwell; G Marshall Lyon; Peter G Pappas; Tom M Chiller; Kathleen A Wannemuehler; Scott K Fridkin; Benjamin J Park Journal: Infect Control Hosp Epidemiol Date: 2008-01 Impact factor: 3.254
Authors: H Saito; D Maruyama; A M Maeshima; S Makita; H Kitahara; K Miyamoto; S Fukuhara; W Munakata; T Suzuki; Y Kobayashi; H Taniguchi; K Tobinai Journal: Blood Cancer J Date: 2015-10-23 Impact factor: 11.037
Authors: Michael J Buege; Anita Kumar; Brianne N Dixon; Laura A Tang; Terry Pak; Jennifer Orozco; Tim J Peterson; Kathryn T Maples Journal: Ann Pharmacother Date: 2020-02-20 Impact factor: 3.154
Authors: Amal A Gharamti; Amy Rao; Paula E Pecen; Andrés F Henao-Martínez; Carlos Franco-Paredes; José G Montoya Journal: Open Forum Infect Dis Date: 2018-10-17 Impact factor: 3.835
Authors: Nicole H Dalal; Graça M Dores; Rochelle E Curtis; Martha S Linet; Lindsay M Morton Journal: Br J Haematol Date: 2020-02-23 Impact factor: 8.615
Authors: Dipti Talaulikar; Ranjana H Advani; Andrew R Branagan; Christian Buske; Meletios A Dimopoulos; Shirley D'Sa; Maria J Kersten; Veronique Leblond; Monique C Minnema; Roger G Owen; Maria Lia Palomba; Alessandra Tedeschi; Judith Trotman; Marzia Varettoni; Josephine M Vos; Steven P Treon; Efstathios Kastritis; Jorge J Castillo Journal: Hemasphere Date: 2020-07-30
Authors: Mikhaila L Rice; Jason N Barreto; Carrie A Thompson; Kristin C Mara; Pritish K Tosh; Andrew H Limper Journal: Cancer Med Date: 2021-06-22 Impact factor: 4.452